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Intraocular pressure: The endless adventure with new challengesThe last decade has witnessed impressing advances in the tech-
nology of digitalized imaging for glaucoma evaluation, the intro-
duction of ﬁxed combination medication, novel surgical
techniques for glaucoma management, and continuing research
to explore risk factors and therapeutic agents that are not intraoc-
ular pressure (IOP) dependent. Yet, the imaging technology cannot
replace expert experience in the diagnosis and follow-up of glau-
coma and IOP-lowering therapy remains the cornerstone in the
management of glaucoma. In this issue, Dr. Shan Lin reviewed the
ﬁndings and limitations of anterior segment optical coherence
tomography regarding its application in glaucoma, and several
authors shared their experience in the control of IOP by using
different treatment modalities.
The history of IOP-lowering therapy for glaucoma can be traced
back to the 19th century, but sound evidence supporting the bene-
ﬁciary effect of IOP-lowering in glaucoma was not available until
the implementation of several prospective, randomized, multi-
center clinical studies. The Ocular Hypertension Treatment Study
(OHTS) demonstrated that a reduction of IOP from baseline by
20% or more decreased the incidence of glaucoma conversion in
5 years from 9.6% to 4.5%.1 For cases with established glaucomatous
visual ﬁeld defects, the Early Manifest Glaucoma Trial (EMGT), the
Collaborative Initial Glaucoma Treatment Study (CIGTS), and the
Advanced Glaucoma Intervention Study (AGIS) all showed a lower
risk of progression in association with a reduction in IOP.2–4 Even
for glaucoma with pretreatment IOP within normal limits, the
Collaborative Normal Tension Glaucoma Study (CNTGS) showed
an IOP reduction of 30% or more beneﬁts those eyes which had2211-5056/$ – see front matter Copyright  2012, The Ophthalmologic Society of Taiwa
http://dx.doi.org/10.1016/j.tjo.2012.08.003prior visual ﬁeld progression, ﬁeld defect threatening the center,
and disc hemorrhage.5
Although the importance of IOP reduction in glaucoma is well
recognized, some uncertainty exists about howmuch the IOP should
be lowered or what numerical pressure measure is safe for most
patients. Target pressure is a range of IOP within that no further
damage to the optic nerve is expected to occur. There are different
ways to estimate target pressure, but no data exist to date to support
an idealapproach.A simpleway is to set the targetbasedontheextent
of existing optic nerve damage. For ocular hypertension, an IOP-
lowering of 20%w25% is suggested for eyes with high risk of conver-
sion to glaucoma if left untreated. For eyes with early, moderate, and
advanced visual ﬁeld defects, to control the IOP within a range not
higher than 18mmHg,15mmHg, and 12mmHg, respectively, is often
recommended. Since large variation in the rate of visualﬁeld progres-
sion exits among patients, ophthalmologists may want to reset the
target pressure when data of subsequent changes in the structure/
function of the optic nerve are available with longer follow-up.
Anongoingdebate about IOP iswhich aspectof IOP, e.g., themean,
the ﬂuctuation, or themaximum,mattersmore in terms of glaucoma
progression.6 Bengtsson and associates6,7 reported that, albeit mean
IOP is a signiﬁcant risk factor for progression, the visit-to-visit IOP
ﬂuctuation during an average of 8-year follow-up was not related
to progression in participants of EMGT. Being launched back in
1992, the EMGT did not incorporate the idea of target pressure;
thus, no further intervention would be suggested after randomiza-
tion as long as progression did not occur and the IOP did not exceed
25 mmHg on two consecutive visits in the treatment arm or
remained 35 mmHg or lower in the observation arm. Later on,
Caprioli and Coldmann8 in a retrospective analysis of patients
enrolled in the AGIS found, in addition to mean IOP and other vari-
ables, visit-to-visit IOP ﬂuctuation was associated with visual ﬁeld
progression in patients with low mean IOP during follow-up
(10.8  2.5 mmHg) but not in patients with high mean IOP
(20.6 4.5 mmHg). They raised a hypothesis that greater IOP ﬂuctu-
ation is damaging in eyes with low mean IOPs; however, when the
mean IOP is higher, the role of IOP ﬂuctuation becomes less impor-
tant. However, in a recent article, which included 607 participants
of the CIGTS, Musch and associates9 found the three IOP summary
measures (range of IOP, ﬂuctuation of IOP, and maximum IOP) were
signiﬁcantlyassociatedwithprogressive visualﬁeld lossover aperiod
of 3- to 9-year among those treated medically (6-year mean IOP,
17.7  2.6 mmHg), but not among those treated surgically (6-year
mean IOP, 14.4  3.8 mmHg). Above all the possible reasons which
may explain the disparity in results across these studies, such asn. Published by Elsevier Taiwan LLC. All rights reserved.
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late various IOP measures, deﬁnition of progression, presence or
absence of IOP-independent risk factors, and methods of statistical
analysis, one fundamental shortcoming of all these studies is that
IOP wasmeasured at a 3- to 6-month interval. As a result, the alleged
mean IOP or ﬂuctuation of IOP probably is not the true average or
variation of pressure acting on the optic nerve head/retinal ganglion
cells throughout the follow-up period.
Although IOP can readily be measured with a variety of tonom-
eters, ophthalmologists in fact know little about their patients’ IOP
proﬁle over time. Due to the variable nature of IOP, it is evident that
the IOP measure obtained in ofﬁce within a short interval of
minutes reveals little of the whole picture of the circadian and
day-to-day variation of IOP.What further hinders us from appropri-
ately estimating patients’ IOP control is that the peak circadian IOP
usually occurs during off-ofﬁce hours. In order to better understand
patients’ IOP proﬁle during the course of daily life, devices that
enable us to measure IOP in a continuous way without interrupting
sleep at night are desirable. After decades of search, a wireless
ocular telemetry sensor which is based on the assumption that
a correlation exits between IOP and corneal curvature has recently
been introduced to continuously monitor IOP in patients with glau-
coma.10,11 Although questions like whether the thickness and
biomechanics of the cornea would affect the accuracy of its
measure remain to be answered, it stands a chance to explore the
enigmatic pressure within the eye.References
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